EFFICACY AND SAFETY OF BOSUTINIB IN PATIENTS WITH RESISTANT CHRONIC MYELOID LEUKAEMIA OR INTOLERANT TO ATLEAST 3 INHIBITORS OF PRIOR TYROSINE KINASE

被引：0

作者：

Valentin, Garcia-Gutierrez ^{[1
]}

Dragana, Milojkovic ^{[2
]}

Luis Felipe, Casado ^{[3
]}

Simone, Claudiani ^{[2
]}

Antonio, Jimenez-Velasco ^{[4
]}

Maria Luisa, Marten-Mateos ^{[5
]}

Concepcion, Boque ^{[6
]}

Alejandra, Martinez-Trillo ^{[7
]}

Isabel, Mata ^{[8
]}

Payer Angel, Ramirez ^{[9
]}

Alberto, Alvarez-Larran ^{[10
]}

Elena, Amutio ^{[11
]}

Garcia Abelardo, Barez ^{[12
]}

Guiomar, Bautista ^{[13
]}

Barela Sabela, Bobillo ^{[14
]}

Ruiz Beatriz, Cuevas ^{[15
]}

Pilar, Giraldo ^{[16
]}

Jose Manuel, Puerta ^{[17
]}

Maria Jose, Ramirez ^{[18
]}

Gerosa Silvana, Saavedra ^{[19
]}

Sandra, Valencia ^{[20
]}

Rivas Fernando, Ortega ^{[21
]}

Mas Ana, Rossel ^{[22
]}

Fabio, Ruiz ^{[23
]}

Juan Luis, Steegmann ^{[24
,25
]}

机构：

[1] Hosp Univ Ramon y Cajal, Serv Hematol & Hemoterapia, Madrid, Spain

[2] Imperial Coll, Hammersmith Hosp, London, England

[3] Hosp Virgen de la Salud, Toledo, Spain

[4] 8Hosp Univ Carlos Haya, Malaga, Spain

[5] Hosp San Pedro de Alcantara, Serv Hematol, Caceres, Spain

[6] Insitute Cotele Oncol, Barcelona, Spain

[7] Hosp Clin Barcelona, Serv Hematol, Barcelona, Spain

[8] Hosp Costa Sol, Malaga, Spain

[9] Hosp Univ Cent Asturias, Oviedo, Spain

[10] Hosp del Mar, Serv Hematol, Barcelona, Spain

[11] Hosp Cruces, Vizcaya, Spain

[12] Hosp Nuestra Senora Sonsoles, Serv Hematol, Avila, Spain

[13] Hosp Univ Puerta de Hierro, Serv Hematol, Majadahonda, Spain

[14] Hosp Valle De Hebron, Barcelona, Spain

[15] Hosp Univ Burgos, Burgos, Spain

[16] Miguel Servet Univ Hosp, Haematol, Zaragoza, Spain

[17] Hosp Univ Virgen de las Nieves, Unidad Gest Clin Hematol & Hemoterapia, Granada, Spain

[18] Hosp Jerez Frontera, Serv Hematol, Cadiz, Spain

[19] Hosp Santa Creu & Sant Pau, Barcelona, Spain

[20] Hosp Segovia, Serv Hematol, Segovia, Spain

[21] Hosp Palencia, Hematol 29Serv, Palencia, Spain

[22] 33Hosp Virgen de la Victoria, Malaga, Spain

[23] Hosp Univ Ramon y Cajal, Serv Hematol & Hemoterapia, Madrid, Spain

[24] Hosp Princesa, Hematol, Madrid, Spain

[25] Hosp Princesa, IIS IP, Madrid, Spain

来源：

HAEMATOLOGICA | 2016年 / 101卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

CO-126

引用

页码：79 / 80

页数：2

共 50 条

[31] Safety and Efficacy of Subcutaneous-Administered Omacetaxine Mepesuccinate in Chronic Myeloid Leukemia (CML) Patients Who Are Resistant or Intolerant to Two or More Tyrosine Kinase Inhibitors - Results of A Multicenter Phase 2/3 Study
Cortes-Franco, Jorge
Raghunadharao, Digumarti
Parikh, Purvish
Wetzler, Meir
Lipton, Jeffrey H.
Jones, Dan
Hochhaus, Andreas
Kantarjian, Hagop M.
Craig, Adam R.
Benichou, Annie-Claude
Humphriss, Eric
Nicolini, Franck Emmanuel
BLOOD, 2009, 114 (22) : 354 - 355
[32] Second-Generation Tyrosine Kinase Inhibitors (Tki) as Salvage Therapy for Resistant or Intolerant Patients to Prior TKIs
Breccia, Massimo
Alimena, Giuliana
MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES, 2014, 6 (01)
[33] Use of second generation tyrosine kinase inhibitors prior to allogeneic stem cell transplantation in chronic myeloid leukaemia
Olavarria, E.
Schleuning, M.
Chalandon, Y.
Onida, F.
Radujkovic, A.
Robin, M.
Kroeger, N.
BONE MARROW TRANSPLANTATION, 2013, 48 : S35 - S36
[34] BCR-ABL kinase domain mutations & SNPs in imatinib resistant or intolerant chronic myeloid leukaemia patients
O'Connor, Lisa M.
Langabeer, Stephen
McCann, Shaun R.
Conneally, Eibhlin
BLOOD, 2007, 110 (11) : 699A - 700A
[35] Cutaneous adverse reactions to tyrosine kinase inhibitors in a cohort of patients treated for chronic myeloid leukaemia
Sears, A.
Orrin, E.
Salisbury, J.
Mufti, G.
De Lavallade, H.
Basu, T.
BRITISH JOURNAL OF DERMATOLOGY, 2014, 171 : 52 - 52
[36] The effectiveness of tyrosine kinase inhibitors and molecular response in newly diagnosed patients of chronic myeloid leukaemia
Fareed, N.
Somroo, N. M.
Quraishy, M. S.
BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 : 210 - 211
[37] A safety review of tyrosine kinase inhibitors for chronic myeloid leukemia
Oezmen, Deniz
Alpaydin, Duygu Demet
Saldogan, Muhammed Ali
Eskazan, Ahmet Emre
EXPERT OPINION ON DRUG SAFETY, 2024, 23 (04) : 411 - 423
[38] SAFETY AND EFFICACY OF SECOND-LINE BOSUTINIB (SKI-606) IN IMATINIB RESISTANT OR INTOLERANT CHRONIC PHASE (CP) CHRONIC MYELOID LEUKEMIA (CML)
Brummendorf, T.
Cortes, J.
Turkina, A.
Masszi, T.
Assouline, S.
Durrant, S.
Volkert, A.
Wang, J.
Arkin, S.
Gambacorti-Passerini, C.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 468 - 468
[39] PATIENT-REPORTED OUTCOMES FROM AN OPEN-LABEL SAFETY AND EFFICACY STUDY OF BOSUTINIB IN PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA RESISTANT OR INTOLERANT TO PRIOR THERAPY
Cortes, J. E.
Mamolo, C.
Su, Y.
Reisman, A.
Shapiro, M.
Lipton, J. H.
HAEMATOLOGICA, 2016, 101 : 458 - 458
[40] Safety and efficacy of third-line bosutinib in imatinib (IM) and dasatinib (DAS) resistant or intolerant chronic phase (CP) chronic myeloid leukemia (CML).
Khoury, H. J.
Kim, D.
Zaritskey, A.
Apperley, J.
Besson, N.
Volkert, A.
Wang, J.
Arkin, S.
Cortes, J. E.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)

← 1 2 3 4 5 →